Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations

D. Clark Files, Michael A. Matthay, Carolyn S. Calfee, Neil Aggarwal, Adam L. Asare, Jeremy R. Beitler, Paul A. Berger III, Ellen L. Burnham, George Cimino, Melissa H. Coleman, Alessio Crippa, Andrea Discacciati, Sheetal Gandotra, Kevin W. Gibbs, Paul T. Henderson, Caroline A.G. Ittner, Alejandra Jauregui, Kashif T. Khan, Jonathan L. Koff, Julie Lang, Mary LaRose, Joe Levitt, Ruixiao Lu, Jeffrey D. McKeehan, Nuala J. Meyer, Derek W. Russell, Karl W. Thomas, Martin Eklund, Laura J. Esserman, Kathleen D. Liu the ISPY COVID Adaptive Platform Trial Network
doi: https://doi.org/10.1101/2022.05.05.22274628
D. Clark Files
1Wake Forest School of Medicine, Winston-Salem NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: clark.files@wakehealth.edu
Michael A. Matthay
2University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Carolyn S. Calfee
2University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Neil Aggarwal
3University of Colorado, School of Medicine, Aurora, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Adam L. Asare
4Quantum Leap Healthcare Collaborative, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeremy R. Beitler
5Columbia University, Irving Medical Center, New York, NY, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul A. Berger III
6Sanford Medical Center, Sioux Falls, SD, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ellen L. Burnham
3University of Colorado, School of Medicine, Aurora, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
George Cimino
4Quantum Leap Healthcare Collaborative, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Melissa H. Coleman
2University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alessio Crippa
7Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Andrea Discacciati
7Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sheetal Gandotra
8University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kevin W. Gibbs
1Wake Forest School of Medicine, Winston-Salem NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Paul T. Henderson
4Quantum Leap Healthcare Collaborative, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caroline A.G. Ittner
9University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alejandra Jauregui
2University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kashif T. Khan
10University of Southern California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan L. Koff
11Yale School of Medicine, New Haven, CT, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Julie Lang
10University of Southern California, Los Angeles, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mary LaRose
1Wake Forest School of Medicine, Winston-Salem NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Joe Levitt
12Stanford Healthcare, Stanford, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ruixiao Lu
4Quantum Leap Healthcare Collaborative, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jeffrey D. McKeehan
3University of Colorado, School of Medicine, Aurora, CO, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Nuala J. Meyer
9University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Derek W. Russell
8University of Alabama at Birmingham, Birmingham, AL, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Karl W. Thomas
1Wake Forest School of Medicine, Winston-Salem NC USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Martin Eklund
7Karolinska Institutet, Stockholm, Sweden
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laura J. Esserman
2University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kathleen D. Liu
2University of California San Francisco, San Francisco, CA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

Abstract

Introduction The COVID-19 pandemic brought an urgent need to discover novel effective therapeutics for patients hospitalized with severe COVID-19. The ISPY COVID trial was designed and implemented in early 2020 to evaluate investigational agents rapidly and simultaneously on a phase 2 adaptive platform. This manuscript outlines the design, rationale, implementation, and challenges of the ISPY COVID trial during the first phase of trial activity from April 2020 until December 2021.

Methods and analysis The ISPY COVID Trial is a multi-center open label phase 2 platform trial in the United States designed to evaluate therapeutics that may have a large effect on improving outcomes from severe COVID-19. The ISPY COVID Trial network includes academic and community hospitals with significant geographic diversity across the country. Enrolled patients are randomized to receive one of up to four investigational agents or a control and are evaluated for a family of two primary outcomes—time to recovery and mortality. The statistical design uses a Bayesian model with “stopping” and “graduation” criteria designed to efficiently discard ineffective therapies and graduate promising agents for definitive efficacy trials. Each investigational agent arm enrolls to a maximum of 125 patients per arm and is compared to concurrent controls. As of December 2021, 11 investigational agent arms had been activated, and 8 arms were complete. Enrollment and adaptation of the trial design is ongoing.

Ethics and dissemination ISPY COVID operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer reviewed medical journals.

Trial registration number Clinicaltrials.gov registration number NCT04488081

Strengths and limitations of this study

  • The ISPY COVID Trial was developed in early 2020 to rapidly and simultaneously evaluate therapeutics for severe COVID-19 on an adaptive open label phase 2 platform

  • The ISPY COVID Adaptive Platform Trial Network is an academic-industry partnership that includes academic and community hospitals spanning a wide geographic area across the United States

  • Of December 2021, 11 investigational agent arms have been activated on the ISPY COVID Trial Platform

  • The ISPY COVID Trial was designed to identify therapeutic agents with a large clinical effect for further testing in definitive efficacy trials—limitations to this approach include the risk of a type 2 error

Competing Interest Statement

DCF has received funding from Quantum Leap Healthcare Collaborative related to this work and from the National Institutes of Health unrelated to this work. DCF has worked as a consultant for Cytovale and Medpace unrelated to this work. ICJME forms from all authors will be uploaded.

Clinical Trial

NCT04488081

Funding Statement

Effort was sponsored by Allergan, Amgen, Takeda Pharmaceutical Company, Implicit Bioscience, J&J, Pfizer, Roche/Genentech, Apotex, Omeros, the COVID-19 Research and Development Consortium, a FAST Grant from Emergent Venture George Mason University, the DoD Defense Threat Reduction Agency (DTRA), The Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) and the Grove Foundation. Effort was sponsored in part by the U.S. Government under Other Transaction number W15QKN-16-9-1002 between the MCDC and the Government. The U.S. Government is authorized to reproduce and distribute reprints for Governmental purposes notwithstanding any copyright notation thereon. The views and conclusions contained herein are those of the authors and should not be interpreted as necessarily representing the official policies or endorsements, either expressed or implied, of the U.S. Government.

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

ISPY COVID operates under a central institutional review board via Wake Forest School of Medicine IRB00066805. Data generated from this trial will be reported in peer reviewed medical journals.

I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • ↵13 Collaborating authors listed in appendix

  • Study sponsor contact information: Paul Henderson PhD, Quantum Leap Healthcare Collaborative, 499 Illinois Street, San Francisco CA 94158, p.henderson{at}quantumleaphealth.org

Data Availability

The trial procedures and protocols are regulated under a central IRB structure at the Wake Forest School of Medicine. All patients (or designated surrogate) entering the portion of the trial that receive an investigational agent undergo patient level consent by study staff and/or study investigators. Protocol revisions are announced at weekly investigator and coordinator meetings and are submitted to the FDA and IRB. No patient level data will be released, and all personal information will remain confidential and de-identified. Results of the agents completing the ISPY COVID Trial will be reported in press releases, scientific abstracts and manuscripts.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Back to top
PreviousNext
Posted May 07, 2022.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations
D. Clark Files, Michael A. Matthay, Carolyn S. Calfee, Neil Aggarwal, Adam L. Asare, Jeremy R. Beitler, Paul A. Berger III, Ellen L. Burnham, George Cimino, Melissa H. Coleman, Alessio Crippa, Andrea Discacciati, Sheetal Gandotra, Kevin W. Gibbs, Paul T. Henderson, Caroline A.G. Ittner, Alejandra Jauregui, Kashif T. Khan, Jonathan L. Koff, Julie Lang, Mary LaRose, Joe Levitt, Ruixiao Lu, Jeffrey D. McKeehan, Nuala J. Meyer, Derek W. Russell, Karl W. Thomas, Martin Eklund, Laura J. Esserman, Kathleen D. Liu
medRxiv 2022.05.05.22274628; doi: https://doi.org/10.1101/2022.05.05.22274628
Digg logo Reddit logo Twitter logo Facebook logo Google logo LinkedIn logo Mendeley logo
Citation Tools
The I-SPY COVID Adaptive Platform Trial for COVID-19 Acute Respiratory Failure: Rationale, Design and Operations
D. Clark Files, Michael A. Matthay, Carolyn S. Calfee, Neil Aggarwal, Adam L. Asare, Jeremy R. Beitler, Paul A. Berger III, Ellen L. Burnham, George Cimino, Melissa H. Coleman, Alessio Crippa, Andrea Discacciati, Sheetal Gandotra, Kevin W. Gibbs, Paul T. Henderson, Caroline A.G. Ittner, Alejandra Jauregui, Kashif T. Khan, Jonathan L. Koff, Julie Lang, Mary LaRose, Joe Levitt, Ruixiao Lu, Jeffrey D. McKeehan, Nuala J. Meyer, Derek W. Russell, Karl W. Thomas, Martin Eklund, Laura J. Esserman, Kathleen D. Liu
medRxiv 2022.05.05.22274628; doi: https://doi.org/10.1101/2022.05.05.22274628

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Respiratory Medicine
Subject Areas
All Articles
  • Addiction Medicine (216)
  • Allergy and Immunology (496)
  • Anesthesia (106)
  • Cardiovascular Medicine (1110)
  • Dentistry and Oral Medicine (196)
  • Dermatology (141)
  • Emergency Medicine (275)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (505)
  • Epidemiology (9796)
  • Forensic Medicine (5)
  • Gastroenterology (481)
  • Genetic and Genomic Medicine (2327)
  • Geriatric Medicine (223)
  • Health Economics (463)
  • Health Informatics (1567)
  • Health Policy (737)
  • Health Systems and Quality Improvement (608)
  • Hematology (238)
  • HIV/AIDS (508)
  • Infectious Diseases (except HIV/AIDS) (11669)
  • Intensive Care and Critical Care Medicine (617)
  • Medical Education (240)
  • Medical Ethics (67)
  • Nephrology (258)
  • Neurology (2155)
  • Nursing (134)
  • Nutrition (340)
  • Obstetrics and Gynecology (427)
  • Occupational and Environmental Health (519)
  • Oncology (1185)
  • Ophthalmology (366)
  • Orthopedics (129)
  • Otolaryngology (221)
  • Pain Medicine (148)
  • Palliative Medicine (50)
  • Pathology (314)
  • Pediatrics (699)
  • Pharmacology and Therapeutics (303)
  • Primary Care Research (268)
  • Psychiatry and Clinical Psychology (2195)
  • Public and Global Health (4685)
  • Radiology and Imaging (786)
  • Rehabilitation Medicine and Physical Therapy (458)
  • Respiratory Medicine (625)
  • Rheumatology (276)
  • Sexual and Reproductive Health (226)
  • Sports Medicine (212)
  • Surgery (252)
  • Toxicology (43)
  • Transplantation (120)
  • Urology (94)